The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1306
Screening for Oral Cancer
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The incidence of oral cancer appears to be increasing, especially in younger patients. Risk factors include use of tobacco and alcohol, and exposure to human papillomavirus.1 ViziLite Plus (Zila Pharmaceuticals) is a combination device that uses fluorescent light and toluidine blue tissue staining to help dentists identify abnormal changes in the mucous membranes of the oral cavity. Originally developed for detecting abnormal growths on the uterine cervix, in 2001 it received FDA clearance for “identification, evaluation, and monitoring of oral mucosal abnormalities in a patient population at increased risk for oral cancer.” The toluidine blue marking system was cleared for inclusion in 2005.

THE TEST — The ViziLite Plus test kit includes an acetic acid solution, a “light stick”, and a marking system. The patient rinses with the acetic acid solution and expectorates. The ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Screening for Oral Cancer
Article code: 1306c
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian